LRIG1 engages ligand VISTA and impairs tumor-specific CD8+ T cell responses

Medicine, Rheumatology and Immunology, Oncology, Life Sciences, Cell Biology, Immunology,
LRIG1   VISTA   tumor-specific   CD8+ T cells   immune checkpoint   anti-tumor immunity   immunotherapy  

Immunotherapy Checkpoint Inhibitors (ICIs, also known as immune checkpoint blockers) are a class of drugs that have achieved significant breakthroughs in cancer immunotherapy in recent years. These drugs mainly work by blocking Programmed Death Protein 1 (PD-1) and Cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4), thereby activating anti-tumor ...

LRIG1 Engages Ligand VISTA and Impairs Tumor-Specific CD8+ T Cell Responses

Medicine, Basic Medical Sciences, Oncology, Life Sciences, Immunology,
LRIG1   VISTA   Tumor Immunotherapy   CD8+ T Cells   Immune Checkpoint Inhibition   Antitumor  

Interaction and Attenuation of Tumor-Specific CD8+ T Cell Responses by LRIG1 and VISTA Academic Background In recent years, the importance of immune checkpoint inhibitors (ICIs) such as Programmed Cell Death Protein 1 (PD-1) and Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) has received increasing attention. These inhibitors significantly improve the s...